PL4229056T3 - Związki triazolopirydynylu jako inhibitory kinaz - Google Patents

Związki triazolopirydynylu jako inhibitory kinaz

Info

Publication number
PL4229056T3
PL4229056T3 PL21805787.5T PL21805787T PL4229056T3 PL 4229056 T3 PL4229056 T3 PL 4229056T3 PL 21805787 T PL21805787 T PL 21805787T PL 4229056 T3 PL4229056 T3 PL 4229056T3
Authority
PL
Poland
Prior art keywords
triazolopyridinyl
compounds
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
PL21805787.5T
Other languages
English (en)
Inventor
Guanglin Luo
Jie Chen
Carolyn Diane Dzierba
David B. Frennesson
Junqing Guo
Amy C. HART
Xirui HU
Michael E. Mertzman
Matthew Reiser Patton
Jianliang Shi
Steven H. Spergel
Brian Lee Venables
Yong-Jin Wu
Zili Xiao
Michael G. Yang
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL4229056T3 publication Critical patent/PL4229056T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL21805787.5T 2020-10-19 2021-10-18 Związki triazolopirydynylu jako inhibitory kinaz PL4229056T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063093463P 2020-10-19 2020-10-19
PCT/US2021/055340 WO2022086828A1 (en) 2020-10-19 2021-10-18 Triazolopyridinyl compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
PL4229056T3 true PL4229056T3 (pl) 2024-06-10

Family

ID=78536657

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21805787.5T PL4229056T3 (pl) 2020-10-19 2021-10-18 Związki triazolopirydynylu jako inhibitory kinaz

Country Status (23)

Country Link
US (2) US11767322B2 (pl)
EP (2) EP4229056B1 (pl)
JP (1) JP2023546166A (pl)
KR (1) KR20230092960A (pl)
CN (1) CN116802181A (pl)
AR (1) AR123793A1 (pl)
AU (1) AU2021364302A1 (pl)
CA (1) CA3196059A1 (pl)
CL (1) CL2023001123A1 (pl)
CO (1) CO2023004926A2 (pl)
DK (1) DK4229056T3 (pl)
FI (1) FI4229056T3 (pl)
HR (1) HRP20240739T1 (pl)
IL (1) IL302113A (pl)
LT (1) LT4229056T (pl)
MX (1) MX2023004492A (pl)
PE (1) PE20240219A1 (pl)
PL (1) PL4229056T3 (pl)
PT (1) PT4229056T (pl)
RS (1) RS65620B1 (pl)
SI (1) SI4229056T1 (pl)
TW (1) TW202233614A (pl)
WO (1) WO2022086828A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20212000T1 (hr) * 2017-02-13 2022-04-01 Bristol-Myers Squibb Company Aminotriazolopiridini kao inhibitori kinaze
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191395A1 (en) 2004-02-16 2007-08-16 Katsuhiro Kawakami Heterocyclic compounds having antifungal activity
WO2006004702A1 (en) 2004-06-25 2006-01-12 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
EP2393813B1 (en) 2009-02-04 2013-07-31 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol
EP2897949B1 (en) 2012-09-18 2018-01-10 Bristol-Myers Squibb Company Iap antagonists
BR112015030774A2 (pt) 2013-06-10 2017-07-25 Bayer Pharma AG novos compostos para o tratamento de câncer
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
US10023576B2 (en) 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
US10214537B2 (en) 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
WO2017077968A1 (ja) 2015-11-05 2017-05-11 住友化学株式会社 縮合複素環化合物
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
WO2018139436A1 (ja) 2017-01-24 2018-08-02 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
HRP20212000T1 (hr) 2017-02-13 2022-04-01 Bristol-Myers Squibb Company Aminotriazolopiridini kao inhibitori kinaze
WO2018237370A1 (en) 2017-06-23 2018-12-27 Accro Bioscience Inc. HETEROARYL COMPOUNDS AS INHIBITORS OF THE NECROSIS, COMPOSITION AND METHOD OF USE THEREOF
WO2019089442A1 (en) * 2017-10-30 2019-05-09 Bristol-Myers Squibb Company Aminoimidazopyridines as kinase inhibitors
WO2019147782A1 (en) 2018-01-26 2019-08-01 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
ES2945220T3 (es) 2018-09-13 2023-06-29 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas
CN112673000B (zh) 2018-09-13 2024-10-18 百时美施贵宝公司 作为受体相互作用蛋白激酶1抑制剂(ripk1)的1h-吲唑甲酰胺
US20230391768A2 (en) 2018-11-07 2023-12-07 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
JP7323637B2 (ja) 2019-03-22 2023-08-08 ▲勁▼方医▲薬▼科技(上海)有限公司 置換複素環式アミド化合物、その調製方法、及びその医薬的使用
US20220380355A1 (en) 2019-10-03 2022-12-01 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
CN114230565B (zh) 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
EP4229056A1 (en) 2023-08-23
EP4364737A3 (en) 2024-08-07
US20240109888A1 (en) 2024-04-04
US11767322B2 (en) 2023-09-26
JP2023546166A (ja) 2023-11-01
TW202233614A (zh) 2022-09-01
US12110290B2 (en) 2024-10-08
AU2021364302A1 (en) 2023-06-22
HRP20240739T1 (hr) 2024-08-30
CO2023004926A2 (es) 2023-05-08
PE20240219A1 (es) 2024-02-16
DK4229056T3 (da) 2024-07-15
KR20230092960A (ko) 2023-06-26
WO2022086828A1 (en) 2022-04-28
FI4229056T3 (fi) 2024-06-18
SI4229056T1 (sl) 2024-06-28
CL2023001123A1 (es) 2023-09-22
PT4229056T (pt) 2024-05-21
AU2021364302A9 (en) 2024-05-02
US20220119388A1 (en) 2022-04-21
CA3196059A1 (en) 2022-04-28
IL302113A (en) 2023-06-01
RS65620B1 (sr) 2024-07-31
EP4229056B1 (en) 2024-04-10
LT4229056T (lt) 2024-06-10
CN116802181A (zh) 2023-09-22
EP4364737A2 (en) 2024-05-08
AR123793A1 (es) 2023-01-11
MX2023004492A (es) 2023-05-10

Similar Documents

Publication Publication Date Title
IL276509A (en) Heterocyclic compounds as kinase inhibitors
IL290508A (en) Heterocyclic compounds as kinase inhibitors
IL290779A (en) Rip1 heterocyclic kinase inhibitors
IL290527A (en) Imidazolyl pyridimidinalamine compounds as cdk2 inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL289439A (en) Heterocyclic compounds as bet inhibitors
IL289389A (en) Heterocyclic compounds as kinase inhibitors
EP3297437A4 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KINASES
EP3578555A4 (en) DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASEACTIVITY
EP4126878A4 (en) COMPOUNDS USED AS CASEIN KINASE INHIBITORS
IL282659A (en) Heterocyclic compounds as bet inhibitors
EP3952865A4 (en) HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS FOR THERAPEUTIC USES
SG11202013016YA (en) Heterocyclic compounds as trk inhibitors
RS65620B1 (sr) Triazolopiridinil jedinjenja kao inhibitori kinaze
EP3927700A4 (en) KINAS INHIBITORS
EP3782987A4 (en) BENZOPYRAZOLE COMPOUND AS A RHO CINEMA INHIBITOR
EP3999072A4 (en) BORONIZED RHO-KINASE INHIBITORS
EP3844166C0 (en) SUBSTITUTED MACROCYCLES USEFUL AS KINASE INHIBITORS
EP3849985A4 (en) ALKINYLNICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS
EP3541806A4 (en) HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
SG11202008705TA (en) Heteroaryl compounds as kinase inhibitor
EP4223754A4 (en) COMPOUND AS AKT KINASE INHIBITOR
ZA202109737B (en) Compound used as kinase inhibitor and application thereof
GB202004960D0 (en) Inhibitor compounds
EP4192816A4 (en) COMPOUNDS USED AS C5AR INHIBITORS